Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 4 Incremental cost-effectiveness ratios (ICERs) and probabilities of each intervention being the most cost effective at various willingness-to-pay thresholds

From: The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD

Intervention

Meta-analysis

ICER

Probability of being cost-effective by willingness-to-pay threshold

$30,000/QALY

$50,000/QALY

$70,000/QALY

$100,000/QALY

Placebo as reference

Placebo

PTC

Reference

35%

10%

3%

0%

MTC

Reference

37%

12%

3%

2%

ICS

PTC

27044

40%

42%

38%

31%

MTC

27614

49%

55%

44%

31%

LABA

PTC

65509

1%

6%

6%

5%

MTC

64339

1%

2%

1%

0%

ICS + LABA

PTC

57933

1%

6%

11%

18%

MTC

52116

0%

7%

1%

29%

LAMA

PTC

38427

21%

34%

43%

46%

MTC

41203

13%

24%

35%

38%

ICS as reference

LABA

PTC

Dominated

--

--

--

--

 

MTC

Dominated

--

--

--

--

ICS + LABA

PTC

89843

--

--

--

--

 

MTC

96749

--

--

--

--

LAMA

PTC

25930

--

--

--

--

 

MTC

57854

--

--

--

--